1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exicure, Inc.
  6. News
  7. Summary
    XCUR   US30205M1018

EXICURE, INC.

(XCUR)
  Report
Delayed Quote. Delayed Nasdaq - 05/20 04:00:00 pm
0.145 USD   +19.83%
05/20Top Premarket Gainers
MT
05/19INSIDER BUY : Exicure
MT
05/17Exicure, Inc. - Reports First Quarter 2022 Financial Results and Corporate Progress
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating

11/23/2021 | 09:29am EDT


© MT Newswires 2021
All news about EXICURE, INC.
05/20Top Premarket Gainers
MT
05/19INSIDER BUY : Exicure
MT
05/17Exicure, Inc. - Reports First Quarter 2022 Financial Results and Corporate Progress
AQ
05/17Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
BU
05/16EXICURE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/16Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/16Earnings Flash (XCUR) EXICURE Reports Q1 Revenue $2.57M
MT
05/16Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
BU
05/13EXICURE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
05/11Thinking about buying stock in Exicure, Vroom, Redbox, Amyris, or Plug Power?
PR
More news
Analyst Recommendations on EXICURE, INC.
More recommendations
Financials (USD)
Sales 2022 17,3 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -0,97x
Yield 2022 -
Capitalization 17,8 M 17,8 M -
Capi. / Sales 2022 1,03x
EV / Sales 2023
Nbr of Employees 40
Free-Float 86,0%
Chart EXICURE, INC.
Duration : Period :
Exicure, Inc. Technical Analysis Chart | XCUR | US30205M1018 | MarketScreener
Technical analysis trends EXICURE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,15 $
Average target price 0,25 $
Spread / Average Target 72,4%
EPS Revisions
Managers and Directors
Matthias G. Schroff President, Chief Executive Officer & Director
Elias D. Papadimas Chief Financial Officer & Secretary
Elizabeth A Garofalo Chairman
Sarah Longoria Chief Human Resources & Compliance Officer
Jeffrey L. Cleland Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EXICURE, INC.-28.25%18
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612